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“It has not escaped our notice that the specific pairing we have postulated 
immediately suggests a possible copying mechanism for the genetic material.” 
[Concluding remark in the paper by Watson and Crick announcing discovery of 
the structure of DNA.]  
— Francis Crick 
In J.D. Watson and F.H.C. Crick, 'A Structure for Deoxyribose Nucleic Acid,' Letter in 
Nature (25 Apr 1953), 171, 
 
 
 
An experiment is a question which science poses to Nature, and a measurement 
is the recording of Nature's answer.  
— Max Planck 
Scientific Autobiography (1949), 110. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my family 
ABSTRACT 
The concept of gene therapy, initially attributed to a technology that would allow the 
correction of inherited genetic disease, has evolved over the years. The realization of 
the immense technical hurdles to achieve genetic correction led to a broadening of the 
concept now including the transfer of genetic material whose expression will 
counteract, mitigate or revert a disease phenotype. This capacity to mitigate or revert 
the disease phenotype has also been achieved by gene expression regulation, at the 
level of the DNA or RNA, by the use of antisense or anti-gene technologies. 
Therefore, at present, gene therapy encompasses not only the introduction and 
expression of therapeutic genes but also the regulation of gene expression itself which, 
when mediated by short oligonucleotides, gave rise to the concept of oligonucleotide-
mediated gene therapy. 
 
The evolution of gene therapy has been in straight connection with developments on 
gene delivery mechanisms and new nucleic-acid based chemistries, which have 
allowed progress in oligonucleotide based antisense / anti-gene methods. 
 
Gene delivery mechanisms have relied mostly on viral-vehicles due to their known 
ability to carry and efficiently deliver their own genetic information to cells, a capacity 
perfected over the period of millions of years. However, production complexity and 
safety concerns have turned the attention to the possibility to use synthetically derived 
vehicles to achieve the same goal. These non-viral gene delivery methods, although 
regarded as safe, have not yet reached the efficiency of viral methods. 
 
Increasing efficiency of non-viral vectors is a process involving mechanisms for 
protection and stabilization of the nucleic acid cargo (DNA, RNA, oligonucleotides) in 
extracellular biological fluids, as well as the intracellular release of the cargo. The cell 
itself presents several barriers for nucleic-acids cargo delivery such as the cellular 
membrane, endocytic vesicle release and the nuclear envelope. 
In this thesis, in paper I, is presented a novel way to deal with nuclear membrane 
translocation when the nucleic-acid cargo needs to access the nuclear interior to 
exercise its action. The developed method uses the cells own nuclear import machinery 
through the use of a synthetic nucleic-acid that acts itself as the nuclear localization 
signal. In paper II, we tackle the barriers formed by the cell membrane and endosomal 
vesicle release. In this paper a new type of cell-penetrating-peptide (CPP) was 
developed for delivery of splice-correction oligonucletides (single-stranded 
oligonucleotide). The CPP efficiently formed complexes with the oligonucleotides 
through non-covalent interactions, and these complexes were shown to have the 
capacity to efficiently be taken up by cells and be released from endocytic vesicles thus 
delivering the oligo to the intracellular environment. 
 
We then turn to oligonucleotide-mediated gene regulation. In paper III we explore the 
use of oligonucleotides to correct an aberrant splicing of the BTK gene leading to loss 
of BTK protein production. The lack of BTK correlates with the absence of circulating 
B-lymphocytes thus causing the disease X-linked agammaglobulinemia. 
 
In paper IV we explore a new LNA-based oligonucleotide capable of enhanced double 
stranded DNA targeting and duplex invasion in order to develop a new tool for the anti-
gene field. 
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1 INTRODUCTION 
The concept of gene therapy was originally attributed to the idea by which the 
transfer of DNA material into cells would serve as corrective measure for genetic 
diseases. This initial concept was soon found to be very technically demanding. Thus, 
another broader definition emerged considering gene therapy as a therapeutic technique 
by which a functional gene is inserted in the human patient cells to correct a genetic 
dysfunction or to give a new function to those cells (1). This concept can be even 
further expanded to include the specific regulation of gene expression mediated by 
DNA or RNA targeted short oligonucleotides, as in antisense or anti-gene therapy.  
However, to achieve the full realization of the gene therapy concept, successful 
means to deliver the nucleic-acid payload, comprising both long double-stranded DNA 
genetic material or short single and double-stranded oligonucleotides, must be in place. 
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1.1 GENE THERAPY 
Already in the 1960’s the initial idea of gene therapy started to emerge in a pure 
speculative manner, with the first ethical debates emerging towards the end of that 
decade. At that time, some of the discussions around the gene therapy concept were 
brought forward in different publications. Some comments and reflections were present 
in statements such as the one by Joshua Lederberg on the “Biological future of man: 
“the ultimate application of molecular biology would be the direct control of nucleotide 
sequences in human chromosomes, coupled with recognition, selection, and integration 
of the desired genes” (2); and Edward Tatum:“…We even can be somewhat optimistic 
about the long-range possibility of therapy based on the isolation or design, synthesis, 
and introduction of new genes into defective cells of particular organs” (3). Until the 
end of that decade others expanded on the idea but gene therapy still remained mostly a 
thing of theoretical debate. 
It was not until the late 1980’s, after the invention of recombinant DNA technology 
(4) and the development of retroviral vectors, which were in common laboratory use by 
the mid 80’s, that the first human trials for gene therapy were performed. Thus in 1989, 
Dr. Steven Rosenberg initiated the first RAC-approved gene therapy trial, which was 
actually a gene-marking study of tumor-infiltrating lymphocytes (TIL) (5). Effectively, 
the first therapeutic gene therapy trial started in 1990 and was conducted by Dr. R. 
Michael Blaese’s group. Using a retroviral vector, the adenosine deaminase gene was 
transferred into T-cells as therapy against severe combined immunodeficiency (SCID). 
The protocol appeared to be safe for the patients, however the clinical benefits were not 
significant (6,7). 
Since that time, and with the human genome coming full circle, several genes 
associated with disease have been identified which translated in many of those genes 
being cloned and made to express by different vectors for therapeutic purposes. This as 
concomitantly led to an increasing number of gene therapy trials using different vectors 
such as: recombinant adenovirus in cystic fibrosis patients (8); adeno-associated virus 
in hemophilia B patients (9); lentivirus for hemophilia patients (10), among others. 
During these times gene therapy has promised much but has nonetheless encountered 
several hurdles. 
Perhaps the most dramatic realization of these setbacks comes from the case of an 
ex-vivo gene therapy trial for SCID-X1. In 2000, Alain Fischer reported the successful 
ex-vivo gene transfer of human gamma chain into CD34+ cells, using a retrovirus 
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vector, to treat infants affected by SCID-X1 (11). The reports on the achievement of 
full correction of disease and phenotype generated great enthusiasm which was later 
turned into great concern when 3 of the children developed T cell leukemia. This was 
attributed to an insertional mutagenesis near the LMO2 oncogene, which led to its 
overexpression (12,13). 
The adverse effect exemplified here is reminiscent of the pathologic nature of the 
parental viruses used in this trial and points out some of the possible limitations when 
using modified viruses for gene transfer. As will be discussed later, this warranted the 
development of non-viral vectors with an inherent lower toxicity profile. 
Throughout the time, gene therapy, initially intended for the treatment of monogenic 
disorders, widened its concept to embrace the treatment of other diseases with complex 
pathologies such as neurodegenerative diseases (eg. Parkinson’s, Alzheimer’s), 
infectious diseases (eg. HIV) and cancer. In parallel, new derivations for gene therapy 
came with the realization of the antisense technology, opening the field of antisense 
gene therapy, which will be discussed in more detail later in this thesis. 
 
1.2 GENE DELIVERY  
The success of gene therapy is strongly dependent of the successful development of 
efficient and safe delivery vectors. Two different lines of research have emerged, one 
focusing on the development of viral carriers and another focusing on synthetic 
delivery systems (non-viral carriers). As already stated, viral vectors were the first to be 
used in clinical trials. Viruses are highly efficient biological machines. They have 
evolved for million years perfecting their capacity to access the host cell and use the 
cells own machinery to aid in their process of replication and infection. So it came as 
no surprise that viruses, as efficient machines for delivery of exogenous genes 
achieving good expression levels, were initially the vectors of choice for gene therapy 
protocols. They are at present still the most widely used in human clinical trials 
worldwide (Fig.1). 
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Figure 1: Type of vectors used in clinical trials worldwide. Information obtained from (14) 
with permission from Journal of Gene Medicine 2011 © John Wiley and Sons Limited. 
 
The most used viral systems include biologically engineered retrovirus, lentivirus, 
adenovirus, adeno-associated virus, and herpes simplex virus (HSV-1) (Fig.1). Despite 
wide use they still possess important limitations, perhaps the most significant being the 
possibility of acute immune responses as a reaction to the viral proteins (especially 
occurring with repeated administrations), the possibility of generating replication-
competent viruses by uncontrolled recombination with homologous sequences in helper 
cell lines, and insertional mutagenesis, which, if occurring close to oncogenes, may 
lead to their activation (15,16). 
One can say that a non-viral approach for gene transfer was already being projected 
by papers in the 1970’s showing specific introduction of genes into mammalian cells by 
chromosome-mediated gene transfer (17) and by purified DNA-mediated gene transfer 
(18). A facilitated delivery of purified DNA into mammalian cells was also present in a 
study by Graham and van der EB in 1973, demonstrating the transfer of viral DNA into 
cells by a process of co-precipitation with calcium phosphate (19). Perhaps the most 
seminal paper on “naked” DNA gene transfer came later from Wolff and colleagues in 
1990 showing expression of reporter genes after direct injection into the mouse skeletal 
muscle (20). 
Development of non-viral vectors has been supported by their recognized ease of 
use, the suitability for high-scale production under GMP manufacturing, lack of 
specific immune responses and a large DNA packing capacity. 
The three main non-viral systems to date are the simple “naked” DNA, cationic 
lipids and cationic polymers. 
Adenovirus 24.1% (n=410) 
Retrovirus 20.8% (n=354) 
Naked/plasmid DNA 18.7% (n=319) 
Vaccinia virus 8% (n=137) 
Lipofection 6.4% (n=109) 
Poxvirus 5.5% (n=94) 
Adeno-associated virus 4.8% (n=81) 
Herpes simplex virus 3.3% (n=57) 
Lentivirus 2.2% (n=38) 
Other categories 5.2% (n=89) 
Unknown 3.2% (n=55) 
  5 
1.2.1 Naked DNA delivery 
Regarding naked DNA delivery it has been already referred that intramuscular 
injections are quite successful in achieving transgene expression, however, the same is 
in general not true when we talk about intravascular injections. This notion has been 
however somewhat contradicted by work from Jon Wolff’s lab and Dexi Liu’s lab 
demonstrating efficient gene expression in hepatocytes following the injection of large 
volumes of plasmid DNA via the mouse hepatic vein and tail vein (21,22). These 
hydrodynamic injection techniques, hence designated due to the relatively big volumes 
of solution injected over a very short period of time, have latter been applied for 
transgene delivery in the kidneys following injection into the renal vein (23), into the 
limb muscle via intra-arterial injections, and to a smaller percentage (10-30%) of tumor 
cells in the brain after injection into the common carotid artery (24). While efficiencies 
have been good the complex surgical nature of these procedures would limit their 
application in clinical settings. This notion has however been disputed by the 
hydrodynamic limb vein (HLV) delivery method where the nucleic acid solution is 
injected into a limb vein while the blood flow in and out of the limb is blocked by a 
tourniquet (25). The significant levels of gene expression, the possibility to target a 
significant muscle mass both to be used as a site of expression of different therapeutic 
proteins or for the actual treatment of muscle diseases, as well as the lack of procedure 
associated toxicity, has prompted the HLV method as a candidate for clinical 
applications (26,27). 
 
1.2.2 Lipoplexes 
The second most characterized method is the use of cationic lipids for complexation 
with the negatively charged DNA molecules, thereby creating the lipoplexes. The first 
lipoplexes were described in 1987 by Felgner et al (28) and they were composed of the 
cationic lipid DOTMA. Since then, progress in lipoplex delivery has presented us with 
the synthesis of new cationic lipids such as eg. DOTAP and DOSPA (29). The 
mechanism of uptake of lipoplexes is thought to be primarily through endocytosis (30), 
as such, the currently used lipoplexes are prepared with neutral or fusogenic helper-
lipids such as DOPE to improve escape from endosomes (31). In-vivo, efficiency of 
lipoplexes as, nonetheless, been limited by problems such as aggregation in blood, non-
specific binding to serum proteins, and low accessibility to the nucleus of non-dividing 
cells (32). One should say though that strategies to overcome some of these problems 
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have been investigated such as the use of PEG as a shielding agent to avoid aggregation 
in blood (33). 
 
1.2.3 Polyplexes 
The third most well characterized method involves the use of cationic polymers, 
which by charge interaction are able to condense DNA into complexes designated by 
polyplexes. This concept was first presented at the same time as lipoplexes, in 1987, by 
Wu and Wu (34). The cationic polymer used at that time was poly-L-Lysine (PLL). 
PLL, together with polyethyleneimine (PEI) and polyamidoamine (PAMAM) are the 
most studied polyplexes. Common to all cationic polymers is their lack of an 
hydrophobic domain, which precludes them from any direct interactions with the 
endosomal membrane leading to fusion or destabilization of the endosomal membrane, 
as is the case with cationic lipids. In the instance of PLL this leads to extremely 
inefficient transfections unless used in conjunction with endosome-lytic agents (eg. 
inactivated adenovirus, (35)). In contrast, PEI, one of the most promising polymers 
capable of achieving remarkable transfection efficiencies, owes its effectiveness exactly 
to the fact that it is capable of promoting its own endosomal escape due to its intrinsic 
endosome-bufferig capacity, often referred to as the proton-sponge effect (36). As 
lipoplexes, polyplexes suffer from non-specific interactions with serum proteins, 
forming aggregates that are rapidly cleared from circulation. Again, PEG has been used 
to shield polyplexes from these non-specific interactions as a way to prolong its 
circulation in blood (37). Other modifications of polyplexes, and also lipoplexes, have 
been the conjugation of cell specific ligands to take advantage of receptor mediated 
uptake mechanisms, thereby achieving cell/organ specific delivery (38-41). 
 
1.2.4 CPPs 
The first cell penetrating peptide (CPP) was reported in 1994, when it was observed 
that a short 16 amino acid long fragment corresponding to the third helix of the 
Antennapedia homeodomain had the capacity to translocate through biological 
membranes (42). This was in line and followed earlier reports from 1988 on the 
capacity of a full-length HIV protein, Tat, to be taken up by cells in culture (43,44). 
A number of peptides with the above described capacity has emerged and, while the 
exact definition of CPP is still debatable they all share some basic features: i) usually 
less than 30 amino-acids long; ii) polybasic and/or amphipatic; iii) capacity to 
translocate across cell membranes and to carry molecules along in this process. 
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Table 1: Examples of some CPP sequences 
CPP SEQUENCE REF 
Penetratin RQIKIWFQNRRMKWKK (42) 
Tat GRKKRRQRRRPPQ (45) 
M918 MVTVLFRRLRIRRACGPPRVRV-NH2 (46) 
Transportan GWTLNSAGYLLGKINLKALAALAKKIL-NH2 (47) 
TP10 AGYLLGKINLKALAALAKKIL-NH2 (48) 
MAP KLALKLALKALKAALKLA-NH2 (49) 
R9 H-RRRRRRRRR-NH2 (50) 
Pep-1 KETWWETWWTEWSQPKKKRKV (51) 
MPG GALFLGWLGAAGSTMGAPKKKRKV (52) 
(RXR)4 H-RXRRXRRXRRXR-OH (53) 
X=6-aminohexanoic acids 
 
Different cargoes have been shown to be able to be transported into cells by CPPs 
such as peptides (54), proteins (55), drugs (56), plasmid DNA (57), liposomes (58), 
nanoparticles (59), oligonucleotides (60,61) and siRNA (62). For the purpose of this 
thesis we will concentrate mainly on delivery of nucleic acid-based cargoes. 
There are basically two strategies for CPP-mediated cargo transport into cells, 
namely, a covalent strategy where the CPP is physically linked to its cargo, or a non-
covalent strategy where the CPP interacts with the cargo mainly through electrostatic 
interactions. 
 
 
 
 
Covalent linkages between CPP and oligonucleotides have been especially useful 
when the oligonucleotide backbone renders them uncharged, such as in the case of 
peptide nucleic acid (PNA) or morpholino (PMO) oligomers. These conjugates have 
been especially useful and have shown promising results in the inhibition of virus 
Figure 1. The two strategies for 
CPP-mediated transport of its cargo 
(in this case oligonucleotides, which 
can be of different chemistries): 
covalent attachment and non-
covalent through electrostatic 
interactions. 
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replication in cell culture and animal models (63), but perhaps the most striking results 
have been achieved in a splice switching strategy to achieve exon skipping of the 
mutated dystrophin gene in Duchenne’s muscular dystrophy (DMD). The DMD 
splicing case will be discussed in more detail in a later section of this thesis. One can 
however say that in comparison to the in-vivo administration of naked PMOs, which 
have resulted in low splice switching levels, CPP-PMO conjugates have shown a 
dramatically improved efficiency of splice switching in a DMD mouse model, with 
restoration of dystrophin protein to more than 50% of normal levels in all peripheral 
muscles and evidence of restored dystrophin protein in the cardiac muscle, which was 
observed for the first time (64-66). 
The non-covalent strategy comes from the simple mixing of the peptide and plasmid 
DNA or oligonucleotide in solution. Normally an efficient complexation requires an 
excess of peptide in relation to the negatively charged nucleic-acid in question. CPPs 
used in a non-covalent strategy are exemplified by the use of MPG (a fusion peptide 
between a hydrophobic segment of HIV-1 gp41 and nuclear localization sequence 
SV40) to form complexes with siRNA, which have been used in-vitro in several cell 
lines (67,68) and in-vivo for targeting OCT-4 in mouse blastocytes (69) or Cyclin B1, 
an essential cell cycle protein, in tumour model mice (70). Polyarginines have also been 
used, achieving very interesting results mostly when conjugated to cholesteryl (Chol-
R9) for the in-vivo delivery of siRNA against VEGF (71), conjugated to a small peptide 
derived from rabies virus glycoprotein (RVG-R9) for siRNA delivery to the CNS by 
crossing the blood-brain-barrier (72), or even conjugated to CD7-specific single-chain 
antibody (scFvCD7-R9) for T cell-specific siRNA delivery (73). Other examples for 
siRNA delivery are penetratin-derived peptides (74), Tat peptide associated with an 
RNA binding motif (75), and transportan derived peptides (62). CPPs can also be used 
in a co-incubation strategy with oligonucleotides and cationic lipids enhancing the 
intracellular delivery in comparison to lipoplexes only (76). 
 
 
1.2.4.1 CPP – Mechanism of uptake 
The mechanism of cellular uptake of CPP and its cargo (either covalently or non-
covalently attached) remains ambiguous. The discussion as led to the idea that both the 
peptide (CPP) and cargo properties can have an influence on the mechanism of uptake. 
Variation on the context of the experimental conditions can also play a fundamental 
role (77). 
  9 
In any case, there are two main pathways indicated as responsible for the uptake, 
one being the direct translocation through the plasma membrane and the other the 
endocytic pathway. Direct translocation would involve destabilization of the plasma 
membrane by direct interaction of the peptides with the lipid bilayer initially at its 
surface. Biophysical methods have proposed different models such as the barrel-stave, 
inverted micelle, and carpet model as types of structures that could allow penetration of 
the peptides into the intracellular milieu (78-80). A study with arginine rich peptides 
employed genetically engineered cells with different endocytic pathways blocked, as 
well as different temperatures to study their translocation. It was concluded that it was 
not dependent on any endocytic or pinocytic pathways (81). The study however did not 
employ any cargo-peptide conjugates, which have been recognized to strongly affect 
the mechanism of uptake (82). 
Concerning the process of endocytosis, which includes phagocytosis and 
pinocytosis, it is a regulated process by which the cell takes up fluids and extracellular 
molecules. Phagocytosis is associated to specialized cells such as macrophages and 
neutrophiles, and is a process used to engulf big particles in an actin-dependent manner 
(83). Pinocytosis occurs in all cell types and 4 distinct mechanisms are associated to it: 
macropinocytosis, clathrin-mediated, caveloae-mediated, clathrin/caveolae-independent 
(84,85). CPPs can in principle use not only a single mechanism of endocytosis but in 
fact take advantage of several mechanisms in parallel as suggested by a study on the 
uptake mechanism of antennapedia/penetratin peptide, nona-arginine (R9), and Tat, 
showing that not a single endocytic mechanism could be resolved, but instead 
macropinocytosis, clathrin and caveloae-mediated endocytosis were occurring in 
parallel (86). 
Since cargo can affect not only the route of delivery but also the extent of delivery, 
every CPP-cargo complex should be investigated individually and through the use of 
several methods in parallel given that there is no single method capable of providing a 
clear-cut view on the exact mechanisms of uptake. Hence a combination of methods 
should be used, perhaps paying special attention to quantitative uptake by 
spectrofluorometry and confocal microscopy (87). In any case the most decisive 
method when it comes to efficacy evaluation is a functional biological assay. One 
typical in-vitro biological assay, recurrently used when assessing the bioavailability of 
CPP-oligonucleotide complexes, employs the HeLa/Luc705 cell line in a Luciferase 
splice correction assay. The cargo molecule is thus a steric block oligonucleotide 
capable of redirecting a pre-mRNA mis-splice occurring in a stably expressed 
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luciferase gene due to the introduction of a mutant β-globin intron in the middle of the 
Luc gene (88). 
 
 
Figure 2. Reporter system for splice switching. A HeLa stable cell line stably expresses a 
Luciferase gene interrupted in the middle by a mutated β-globin intron 2. The mutation at 
position 705 produces a 5’-SS and activates a cryptic 3’-SS leading to the production of an 
aberrantly spliced mRNA unless the splice site is masked by a splice correcting oligo (ON 705) 
(88). 
 
 
1.2.5 Intracellular barriers – The nuclear envelope 
Nuclear import of therapeutic molecules is of great importance for the area of gene 
delivery. This is especially true in non-viral vector development since these transport 
systems need to mimic most of the virus strategies used to overcome several cellular 
barriers, of which the nuclear membrane is the ultimate one. 
 
The nuclear membrane, also named nuclear envelope, is bilayer in nature and acts as 
a molecular sieve tightly regulating the traffic of molecules in and out of the nucleus. 
The high level of control in the transport of molecules from and to the nucleus is of 
uttermost importance to eukaryotic cells allowing them to achieve a strict regulation of 
gene expression by controlling the entry of key signalling molecules to the nucleus as 
well as being critical for a correct cell division (89,90). The “door” through which the 
nucleo-cytoplasmic transport occurs is a large multiprotein channel that spans the 
double-lipid bilayer of the nuclear envelope and is designated nuclear pore complex 
(NPC). Studies in the vertebrate Xenopus laevis have revealed a molecular mass of 
around 112 MDa (91) whereas in the invertebrate Saccharomyces cerevisiae it was 
determined to be around 66 MDa (92). There are approximately 2000-4000 NPC in a 
nuclear envelope, each consisting of multiple copies of around 30 different proteins 
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known as nucleoporins (Nups) (89,93). This doorway (the NPC) acts as a diffusion 
channel, which, with a diameter of around 90-100Å, allows the passage of 
macromolecules of roughly 40KDa while larger cargoes with diameters up to 390Å 
require an active transport mediated by specific import/export receptors (94,95). The 
selectivity of the pore is achieved by the presence of natively unfolded Nup modules 
containing numerous FG repeats, each unit containing a hydrophobic cluster, typically 
of the sequence FG (phenylalanine-glycine), GLFG (L, leucine), or FxFG (x, any), 
embedded into a more hydrophilic spacer sequence (96). While still under debate, it is 
considered that FG repeats can form a very selective hydrogel with capacity to interact 
with nuclear transport receptor proteins (NTRs) whilst still remaining firm barriers 
towards inert macromolecules lacking any transport capabilities, and even possessing 
“self-healing” properties that allows it to immediately reseal behind a translocating 
molecule (97,98). 
The transport mechanism itself has as minimum requirements the presence of a 
transport signal and a shuttling receptor capable of recognizing that signal. Basically, 
proteins to be transported in or out of the nucleus need to have present a specific 
amino-acid sequence designated nuclear localization signal (NLS) or nuclear export 
signal (NES), respectively.  
This thesis will focus on the nuclear import mechanism. 
The classic mechanism of nuclear import is mediated by NLS peptides that can contain 
one or two clusters of basic residues. The prototypical monopartite NLS, described in 
the mid 80’s, is exemplified by the Simian Virus 40 (SV40) large T antigen NLS which 
contains a cluster of 4-5 consecutive positively charged amino-acids (99,100). The 
prototypical bipartite NLS comes from the example of nucleoplasmin which has a 
second, generally smaller, cluster located 10-12 residues downstream of the first (101). 
A transport adapter, importin-α, directly recognizes these signals, through its two 
specific lysine-binding pockets located at the surface (102,103). Additionally, importin-
α contains at the N-terminus a domain for direct binding to the carrier protein importin-
β (also named karyopherin β1) (104). This domain, the importin-β binding domain 
(IBB), contains a cluster of basic amino-acids, and is normally bound to the NLS 
binding pockets of importin-α directly competing with the NLSs (105). This points to 
the idea that NLS binding to importin-α is facilitated when it is already in complex 
with importin-β due to the delocalization of the IBB domain out of the NLS binding 
pockets. This suggests in turn that in the cell, NLS containing proteins bind primarily to 
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the importin-α/β complex. The 
cargo-importin-α/β is then able to 
translocate through the nuclear pore 
into the nucleus via direct 
interactions of the importin-β with 
the NPC nucleoporins. 
Directionality of transport is 
assured by an energy dependent 
process that maintains high 
concentration levels of RanGTP in 
the nucleus, responsible for 
inducing the dissociation of the 
cargo-import complex (106). The 
mechanism is as follows: once the 
cargo-importin α/β complex is 
imported into the nucleus, RanGTP 
binds to importin-β leading to the 
release of the cargo and dissociation 
of the whole complex. Importin-β 
complexed with RanGTP is then 
recycled to the cytoplasm, whereas 
importin-α is exported complexed 
with the β-karyopherin CAS and 
RanGTP. The importins-RanGTP 
complexes are dissociated in the 
cytoplasm after the hydrolysis of RanGTP to RanGDP, which is facilitated by RanGAP 
at the cytoplasmic face of the NPC. RanGDP is then imported back to the nucleus to be 
phosphorylated again to RanGTP by the guanine exchange factor (RanGEF) RCC1. 
Thus, the concerted action of RanGAP (GTPase-activating protein), which is found 
predominantly in the cytoplasm, and RanGEF (guanine-nucleotide-exchange factor), 
which is found predominantly in the nucleus, generates the necessary asymmetrical 
distribution, with RanGDP located in the cytoplasm and RanGTP within the nucleus 
(106).  
Figure 3. Mechanism of nuclear import. An NLS 
bearing cargo is recognized by the Imp-α/β 
complex. The cargo-Imp-α/β complex is 
translocated thorugh the nuclear pore (NPC). Once 
in the nucleoplasms it is disassembled by the 
binding of RanGTP to Imp-β. Imp-α and Imp-β are 
transported back to cytoplasm where RanGTP 
hydrolysis by RanGAP allows the importins to be 
free again to restart the process. 
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Not all NLS bind to importin-α as the first step. Instead they can bind directly to 
importin-β, bind to transportin (karyopherin β2) or bind to different import adaptor 
proteins like snurportin (SPN1). Table 2 presents a list with NLS sequence examples 
and carrier proteins used for their nuclear transport. 
 
Table 2: Examples of Nuclear localization signal (NLS) sequences and import factors involved 
in the nuclear translocation  
CARGO Peptide sequence motifs / Domains Transport Factors 
SV40 large T-antigen PKKKRKV Imp α/ Imp β 
Myc PAAKRKVLD Imp α / Imp β 
HIV-1 Rev RQARRNRRNRRRRWR Imp β 
HIV TAT GRKKRRQRRRPPQC Imp β 
Nucleoplasmin KRPAATKKAGQAKKKKLDK Imp α / Imp β 
hnRNPA 1 (M9 NLS) 
GNQSSNFGPMKGGNFGGRSSGPYG
GGGQYFAKPRNQGGY 
Transportin 
U snRNP m3G-CAP and Sm core proteins Snurportin / Imp β 
 
1.2.5.1 Nuclear Import of Small Nuclear RNAs 
Of relevance to the work presented in this thesis is a more detailed view on the 
nuclear import of snRNAs, specifically, uridine rich small nuclear RNAs (U-snRNAs). 
U-snRNAs are a major component of the spliceosomal U-snRNPs undergoing a 
complex biogenesis process 
both in the nucleus and 
cytoplasm. U snRNAs U1, U2, 
U4 and U5 are synthesized in 
the nucleus by RNA 
polymerase II where they 
acquire a 7’-monomethylated 
(7mG) cap structure at their 5’-
end. This 7mG-cap participates 
in the snRNA export to the 
cytosol by action of a nuclear cap-binding complex (CBC) (107). Once in the 
Figure 4. 2,2,7-trimethylguanosine cap structure 
(m3G-CAP). 
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cytoplasm the snRNAs associate with the survival of motor neurons (SMN) complex 
formed by the SMN proteins and at least six distinct Gemin proteins (108). The 
assembly of this complex on the snRNA promotes the subsequent maturation events 
which ultimately lead to the recruitment of a hypermethylase (TGS1) that catalyzes the 
transfer of two additional methyl groups to the 7mG-cap converting it to the 2,2,7-
trimethylguanosine (m3G) cap (109,110). The m3G-cap acts as an independent NLS 
signal, which together with a less defined NLS signal present in SMN associated 
proteins (111) results in re-import to the nucleus. The m3G-cap structure is specifically 
recognized by the snurportin protein import adaptor (SPN1) (112,113) which then 
binds to importin-β (114). Analysis of an m3G-cap analogue (m3GpppG) bound to the 
C-terminal domain of SPN1 shed some light on the structural basis for the import of the 
m3G-cap while 7mG-cap is excluded. It was reported that the two extra methyl groups 
on the guanosine allow Van der Waal contacts with Tryp residues in the SPN1 binding 
pocket. More importantly was the fact that binding of the m3G-cap to SPN1 requires 
hydrophobic interactions that do not allow any water molecules to be present. The 
m3G-cap having a smaller hydration shell than 7mG, due to the dimethylated N2, has a 
big energetic advantage (113). In the same study, crystallization with an extended m3G-
cap containing 3 additional methylated residues similar to naturally occurring snRNA 
(m3GpppAmUmAm) was not possible, however determination of dissociation constants 
led to the observation that the extended cap had around 5x more binding affinity to 
SPN1 than the dinucleotide cap leaving open the question on the structural role of these 
extra 2’-O-methylated residues on the overall binding to SPN1. 
It is of interest to add that this complex is thought to mediate an energy-independent 
nuclear translocation of snRNPs (115,116).  
The m3G-cap remains, so far, the only fully characterized nucleic acid structure 
capable of acting independently as an NLS signal. 
1.2.5.2 Nuclear Delivery of exogenous nucleic acids 
The efficiency of gene delivery is strongly connected to the capacity of the 
exogenous nucleic acid material to be translocated across the nuclear envelope. During 
common in-vitro laboratory procedures for cell transfection the cells are usually 
actively dividing, meaning that the nuclear envelope is broken down in each mitosis 
phase and reassembled after M phase completion. This process translates into an easy 
access of any nucleic acid (eg. plasmid DNA) to the nucleus during the M phase and 
concomitantly high transfection efficiencies. Such is not the case in primary cells, or 
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terminally differentiated cells, and therefore the nuclear membrane barrier strongly 
affects in-vivo gene delivery efficiencies (unless the target cells are actively dividing 
cancer cells). 
It is therefore with no surprise that some of the efforts in the development of non-
viral vectors have been directed towards improvements in nuclear targeting. Most of 
the approaches to tackle this problem have concentrated on hijacking the intracellular 
mechanisms and proteins involved in nuclear import. 
The first evidence that DNA could indeed translocate through the nuclear pores 
came from a study by Wolff and co-workers where they microinjected plasmid DNA 
into the cytosol of postmitotic primary rat myotubes. Plasmid DNA was indeed found 
in the nuclei of the cells, however it is also a fact that large amounts of DNA were 
microinjected, most of it was residing at the site of injection and the process was 
extremely dependent on the injection site being close to the nuclear envelope. 
Nevertheless, the process was found to be energy dependent and inhibited by wheat 
germ agglutinin (WGA, a blocker of transport through the nuclear pores) indicating that 
the transport process was closely following the entry route of karyophilic proteins 
(117). 
Several strategies have thus tried to use the entry route of karyophilic proteins to 
increase nuclear import of DNA. Most have relied on the import mechanics of NLS 
signals and can be divided into different categories: I) Non-covalent association of NLS 
to DNA; II) Covalent attachment of NLS to DNA; III) Association of DNA with 
proteins with nuclear import capacity.  
Figure 5. Examples of methods to 
enhance nuclear import of DNA. A) 
Non-covalent electrostatic association 
with NLS peptides; B) Sequence-
specific association through NLS-
conjugated PNA-anchors; 
C) Covalent coupling of NLS through 
chemical or photoactive groups; D) 
NLS sequence ligated to hairpin 
sequences on the ends of linear DNA 
sequences E) Ionic association with 
karyophilic proteins; 
F) DNA bearing DNA-Targeting-
Sequences recognized in the cytoplasm 
by transcription factors that will mediate 
nuclear import through import protein 
interactions. 
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Non-covalent association 
Some strategies have relied on the electrostatic association of the common SV40 
NLS peptide to plasmid DNA for uptake and nuclear localization in zebrafish (118) or 
even tetrameric versions of the same NLS separated by glycine units with capacity to 
complex plasmid DNA creating polyplexes that efficiently transfected various cell lines 
such as 16HBE14o-, HeLa S6, and Cos7 cells (119). Another approach used the M9 
NLS peptide conjugated to a scrambled version of the SV40 NLS which was employed 
in this case has a simple cationic domain to allow interaction of the peptide conjugate 
to the DNA. The DNA-peptide complex was used together with lipofection to transfect 
highly confluent bovine aortic endothelial cells (BAECs) (120). 
Instead of using the NLS peptides as the condensing/complexing agents them-
selves, other strategies have used condensing components like polylysine conjugated to 
the SV40 NLS peptide (121). 
Another alternative to the unspecific electrostatic association is the use of sequence-
specific DNA analog anchors conjugated with NLS peptides. In one example, peptide 
nucleic acid (PNA) clamps were conjugated to SV40 NLS peptide and associated to 
plasmid DNA via sequence specific hybridization. These complexes were transfected 
into cells by the use of PEI and an increase in expression was seen over naked 
(unhybridized) DNA (122). A sequence specific association was also achieved by the 
use of triplex forming oligonucleotides (TFOs) that were ligated in a subsequent step to 
a hairpin oligo conjugated to an NLS peptide. These padlock conjugates were then 
transfected via lipofection but no increase of expression was observed (123). 
 
Covalent strategies 
Direct conjugation of NLS peptides to DNA could offer a more stable alternative to 
the non-covalent strategies when the plasmid is en-route through the cytoplasm towards 
the nucleus. 
Some approaches involved direct conjugation through photoactivation of a p-azido-
tetrafluoro-benzyl modified NLS peptides to plasmid DNA while studying optimal 
spacer lengths between NLS to the anionic DNA backbone. The results in terms of 
nuclear uptake were however far from satisfactory although association with importins 
was seen in in-vitro tests (124,125). The observation that importin was binding but no 
functional effect in cells were seen can correlate to the fact that the unspecific covalent 
attachment of NLS peptides to plasmid DNA could render them transcriptionally 
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inactive but also to the difficulty of DNA to efficiently overcome the crowded 
cytoplasm and travel towards the nuclear periphery (126). 
On the other hand, a correlation between NLS mediated DNA nuclear import and 
size has been made. A 900bp GFP-expression cassette was covalently labeled with 
biotin through the use of a PCR method with biotinylated-primers and subsequently 
incubated with NLS conjugated streptavidin. Microinjections into living cells resulted 
in increased uptake and expression of the GFP cassette in the nucleus (127). 
A direct conjugation of NLS peptides to oligo primers has also been used in a PCR 
approach to label a Luciferase expressing plasmid. In this case, both electroporation 
and a cationic polymer based delivery system were used for transfection but no 
significant enhancement of gene expression was seen when using the NLS-conjugated 
plasmid (128). 
Another method for specific association of NLS to plasmid DNA has been through 
the use of TFO involving triple helix formation and subsequent covalent bonding by 
photoactivation. Delivery to NIH3T3 by lipoplex formation was used and the modified 
plasmids were expressed indicating no loss of transcription activity. On the other hand 
there was no increase of gene expression when using the NLS modified plasmids (129). 
 
Association with proteins with import capabilities 
Association of DNA with viral proteins has also been investigated. One such case is 
exemplified by the complexation of DNA with the major core protein VII of adenovirus 
type 2 (Ad2). Adding the complexes directly to the cell medium resulted in rapid (2-4h) 
transport into the cell and the nuclei of about 40% of the cells (130). However, it has 
been recognized that there might have been an overestimation of the result due to 
plasmid residence at the nuclear envelope and not exactly inside the nucleus. Another 
example comes from the use of HIV-1 integrase (IN) enzyme for complexation and 
nuclear localization of DNA in a process mediated by the importin α/β complex. The 
IN alone was rapidly accumulating in cell nuclei and when in complex with DNA it 
maintained the ability to interact with importin α/β. A critical basic region  (K186RK) 
mediating the nuclear translocation was identified. The studies were however only done 
in an in-vitro system using semi-intact cells (131). 
The use of histones has also been investigated in a way certainly inspired by their 
natural ability to condense DNA as one of their functions in the nucleosome particles. 
The 4 core histones H2A, H2B, H3 and H4, are transported from the cytoplasm to the 
nucleus by an NLS-dependent process (132,133). The linker histone H1 although not 
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having a clear sequence resembling classical NLS has a high density of basic amino-
acids thought to be responsible for the nuclear localization activity (134) and has 
additionally been shown to interact with an importin beta/importin 7 complex (135). 
Several of the histones have been used to complex and mediate transfection of DNA 
into several cell lines and primary cells in a process coined histonefection (136). In one 
example, a truncated H1.4 construct encompassing 387 nucleotides at the 3′-end was 
used to efficiently deliver DNA and siRNA to different cell lines in a process that 
seemed to be dependent on exogenous CaCl2 addition (137). One inherent problem of 
using histonefection is the fact that an excess of extracellular histones could interfere 
with endogenous histones and normal DNA replication and transcription (136). 
A strategy that has been showing some potential is making use of the association of 
transcription factors to the DNA by specific interaction with special sequences in the 
DNA designated DNA-targeting-sequences (DTS) (138). Work by Dean et al showed 
that DNA could be imported into the nucleus in a sequence specific way. Initially, 
microinjection of the SV40 5.2Kb genome into the cytoplasm of growth-arrested cells 
resulted in localization into the nucleus in 6-8h, detected by in-situ hybridization. In 
contrast, two other plasmids containing only bacterial and bacteriophage sequences 
remained in the cytosol (pBR322 and pBluescript). The origin of replication and early 
and late promoter sequences were then identified in the SV40 DNA that allowed 
nuclear import, moreover, this process was found to be dependent on active 
transcription (139). In a follow-up study they found that cloning of the SV40 enhancer 
sequence, containing the 72bp enhancer repeats, in several plasmids, was the minimum 
condition necessary for efficient nuclear import (140). The working model for this 
transport is based on the association of transcription factors in the cytosol (where they 
are expressed) to specific binding sequences in plasmid DNA. Since transcription 
factors bear NLS signals, they would carry with them the DNA to which they are 
bound during the nuclear import process (138). 
Other sequences have been proposed to mediate DNA nuclear import. Mesika et al 
demonstrated that DNA vectors containing 5x NF-kβ binding sites had a 12-fold 
increase in nuclear entry in comparison to plasmids lacking the binding sites. This 
increase could be further enhanced by stimulation with an NF-kβ activator (TNF-α) 
(141). 
Of added interest is the fact that the DTS mediated nuclear import can be used to 
achieve a cell specific import and thus gene expression. Such is the case reported by the 
use of the smooth muscle gamma actin (SMGA) promoter. A 176 bp portion of the 
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smooth muscle g-actin (SMGA) promoter was shown to be sufficient condition for the 
nuclear import of DNA specifically in smooth muscle cells. Binding sites for serum 
response factor (SRF) and NKX3-1/3-2 within this DTS were required for import 
(142). Both the SV40 and SMGA DTSs have been used in-vivo. Plasmids containing 
the SV40 DTS element downstream of the polyA site were electroporated into the 
intact mesenteric vasculature of the rat. DTS containing plasmids gave 10- and 40-fold 
higher Luciferase expression levels at 2 and 3 days post-transfection, respectively 
(143).  The same method has been used together with plasmids containing the SMGS 
DTS. GFP gene expression was found to be cell specific, restricted to SMαA-
expressing smooth muscle cells in the vessel wall, whereas none of the cells in the 
adventitia showed GFP expression (144). 
At the moment, however, there seems to be no common features between promoters 
allowing to identify, beforehand, promoter or promoter regions that can support nuclear 
import of plasmid DNA. 
 
1.3 NUCLEIC ACIDS FOR GENE MODULATION 
The concept of oligonucleotide (ON) gene therapy basically started with the birth of 
the antisense field when Zamecnik and Stephenson, in 1978, reported on the inhibition 
of virus replication in cell culture by a DNA oligonucleotide complementary to the 
target RNA (145). 
The idea on the use of oligonucleotides for therapeutic purposes hence emerged, 
backed up by the development, around the same time, of a method for ON solid phase 
synthesis (146). 
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Figure 6. Antisense and anti-gene mechanisms overview. In the cytoplasm ssAONs can 
mediate translation arrest by steric blocking; siRNA mediates mRNA cleavage by recruiting the 
RISC complex and Argonaute 2 which has hydrolyzing activity; ssAONs forming a DNA-RNA 
hybrid duplex recruit RNase H which then cleaves the mRNA. In the nucleus ssAONs can 
invade the duplex DNA and arrest transcription initiation or elongation; TFOs binding to the 
major groove of dsDNA can create a steric block which can arrest transcrition initiation or 
elongation; siRNAs directed to promoter regions can activate epigenetic remodeling complexes 
inducing heterochromatin formation and silencing of gene expression. 
 
The antisense concept was based on the notion of hybridization of an ON with RNA 
for blocking its function. The therapeutic ON field continued to advance and besides 
the classical antisense concept, other technologies have been developed using nucleic-
acids for designing RNA-cleaving Ribozymes, DNAzymes and siRNA, all with 
capacity to suppress RNA translation. However, also ONs with DNA as their target 
have been designed for suppression of transcription, thereby achieving gene down-
regulation. 
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1.3.1 Classical Antisense 
Classical antisense oligonucleotides (AON) can operate using basically two 
mechanisms. The first mechanism consists on the simple steric block of ribosomal 
activity on mRNA thereby inhibiting translation. Steric block is also used for inhibition 
of splicing (or splice redirection) which will be covered in its own section in this thesis. 
Translation inhibition by steric block has been achieved by targeting ONs to 
different regions in the mRNA. Thus, the 5’-UTR (147-149), translation initiation sites 
(150) and internal ribosome entry sites (151) have all been targeted by steric block 
oligos. 
The majority of these early-days translation inhibition antisense oligos were used in 
cell-culture systems, and although regarded as not extremely efficient the development 
of new nucleic acid analogues provided new tools to increase this mechanism efficacy. 
Perhaps the most striking examples come from the use of morpholino oligomers 
(PMO), which will be discussed later. 
The second mechanism, in contrast to the occupancy-mediated antisense just 
described, is based on the degradation of the target RNA. Hybridization of the AON to 
the target RNA creates an RNA-DNA hybrid that is specifically recognized by the 
enzyme RNase H which promotes the cleavage of the RNA strand. There are two 
classes of RNase H enzymes identified in mammalian cells differing in their cofactor 
requirements and activity (152-154). It is however recognized that RNase H1 is the 
enzyme playing the dominant role in the AON activity (155). RNase H2 is thought to 
be unavailable to participate in the hydrolysis of RNA, in AON-derived RNA-DNA 
hybrids,, due to the fact that it seems to be associated with chromatin, where it 
participates in DNA synthesis processes (156). 
Activity of RNase H1 is very much dependent on the specific structure adopted by 
the RNA-DNA hybrid. An RNA-DNA heteroduplex adopts an eastern O-4’-endo sugar 
pucker, resulting in a helical conformation in which the RNA strand adopts A-form 
geometry and the DNA strand shares both the A- and B-form helical conformations. 
The adoption of this O-4’-endo conformation by the DNA partially narrows the major 
groove which is an essential condition for the tight binding of RNase H1 to the 
heteroduplex and catalytic activity (157). These specific structural requirements are the 
reason why RNase H can distinguish RNA-DNA from RNA-RNA or DNA-DNA 
homoduplexes but also lead to a fundamental limitation in AON activity. In fact, new 
generation of AONs, relying on nucleic acid analogues that confer AONs with a 
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structure that diverges from the DNA type, are not active for RNase H cleavage. The 
nucleotide features for an active AON were thus determined to be: i) a 
conformationally flexible sugar producing an O-4’-endo pucker when hybridized to 
RNA, ii) no sterically bulky 2’-substituents, and ii) a conformationally rigid phosphate 
backbone (158). This would preclude the use of many interesting new nucleotide 
analogues such as MOE (2’-methoxyethyl), PNA and LNA, however, a new AON 
design was developed where the analogues are only introduced as blocks at the 5’- and 
3’-ends while the central region of the AON maintains DNA or DNA-like nucleotides. 
This created the concept of gap-mers 
which can still harness the positive 
properties (such as nuclease resistance 
and better duplex binding affinities) of 
the new nucleic acid analogues and 
support RNase H activity at the same 
time (159,160). More detail on some of 
these properties will be given further in 
the thesis. 
The first (and so far only) approved 
antisense drug, Vitravene (formivisen sodium) (161), is a fully phosphorothioate DNA-
AON using the RNase H mechanism for the treatment of cytomegalovirus (CMV) 
retinitis in patients with AIDS . 
 
1.3.2 siRNA 
Another strategy for suppressing gene expression involves the use of yet another 
cellular enzyme to cleave the target RNA in a process that is initiated or mediated by 
dsRNA. This mechanism was recognized by Fire and Mello in 1998 when they injected 
a dsRNA into C. elegans which led to the sequence specific down-regulation of a target 
gene harboring the same sequence as the dsRNA (162). This marked the discovery of 
the RNA interference mechanism, for which the two investigators were awarded in 
2006 the Nobel Prize in Physiology and Medicine. It was initially recognized that the 
dsRNA molecules were being processed to 21-28nt small interfering RNAs (siRNAs), 
which were then guiding the sequence specific degradation of mRNA (163,164). The 
elucidation of the structure of siRNAs was pivotal for the subsequent discovery that the 
RNAi mechanism was active in mammalian cells (165), as any attempts to introduce 
long dsRNA into mammalian cells would lead to the induction of the antiviral 
Figure 7. Schematic representation of a gap-
mer for inducing RNase H mRNA 
degradation. 
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interferon response and usually cell death (166). The current status of knowledge for 
the RNAi pathway can be summarized as following: Initially dsRNA is cleaved by the 
Dicer enzyme generating 21- to 28-nucleotide siRNA duplexes that contain 2 
nucleotide 3′-overhangs with 5′-phosphate and 3′-hydroxyl termini. This product is then 
loaded into a protein complex named the RISC loading complex of which the protein 
Argonaute 2 (Ago2) is a key component. The RISC complex then separates the two 
strands and an active RISC complex containing the guide (antisense) strand is 
produced. The active RISC recognizes the target mRNA through hybridization with the 
guide strand and Ago2 catalyses the cleavage of the target mRNA. The cleavage itself 
occurs 10 nucleotides from the 5’-end of the guide siRNA strand (167). 
The use of synthetic siRNAs exogenously administrated to cells is an easy way to 
achieve down-regulation of target genes and the rules for the design of these efficient 
synthetic oligos have been investigated. Thus, a synthetic siRNA should have a low 
G/C content, have a bias towards low internal stability at the sense strand 3′-terminus, 
lack of inverted repeats, and sense strand base preferences with an A nucleobase at 
positions 3, “U” at position 10, a base other than “G” at position 13 and “A” at position 
19 (168). 
Recently, siRNAs designed against promoter regions have also been found to induce 
gene silencing in mammalian cells through a transcriptional mechanism as opposed to 
post-transcriptional, designated by transcriptional gene silencing (TGS) (68,169). This 
silencing comes about due to heterochromatin formation, which occurs by the action of 
an epigenetic remodeling complex guided to the specific target loci by the small RNA. 
Argonaute 1 (Ago1) seems to be involved directly in this remodeling complex since 
after 24h exposure to the small RNA it increases its presence at the promoter with 
subsequent increase in H3K27 trimethylation and H3K9 dimethylation (170). When 
targeting is maintained for at least 3 days, DNA methylation increases at the target 
locus which seems to correlate to long term silencing (171). Interestingly it now seems 
that for RNA-targeted TGS to take place there needs to be transcription going through 
the promoters with production of promoter-associated RNAs (pRNAs) which can then 
be recognized by the antisense strand of the siRNA (172,173). This mechanism brings 
new insights into the use of single-stranded antisense oligonucleotides for targeting 
pRNA in order to achieve long-term gene silencing without even having to resort to 
siRNAs. A study where only the 21-bp antisense (guide) strand was necessary to direct 
TGS hints at this possibility (174). 
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1.3.3 Splice switching 
Manipulation of the process of RNA splicing has a tremendous potential which can 
be immediately recognized by the fact that around 95% of human genes are 
alternatively spliced and at the same time 50% of disease causing mutations affect 
splicing (175,176). 
Alternative splicing is a way of regulating gene expression by generation of multiple 
proteins from a single pre-mRNA transcript. Splicing and alternative splicing rely on 
essential sequence elements in pre-mRNA 
such as splice-sites, branch points, 
polypyrimidine tracts, and auxiliary 
splicing enhancer or silencer sequences 
existing both in exons and introns 
(designated exonic/intronic splicing 
enhancers, ESE/ISE or exonic/intronic 
splicing silencers, ESS/ISS). These 
sequences are recognized by the splicing 
machinery and auxiliary proteins such as 
SR proteins and hnRNP (177). 
To affect mRNA splicing, AONs need to 
hybridize to the target pre-mRNA and act 
through a steric-block mechanism without 
eliciting any RNA degradation pathway. 
Thus, there is a potential to use AON 
technology for diseases caused by aberrant 
splicing or when altering normal splicing 
can mitigate a disease-causing mutation. 
These specific AONs are frequently named 
splice-switching oligos (SSOs) and can 
operate in different ways such as: a) 
blocking of a mutation-induced cryptic 5’-
or 3’-splice site for restoration of normal 
splicing; b) blocking of exon-intron 
junctions and/or ESEs to induce exon skipping (this strategy can be used to exclude 
Figure 8. Overview on splicing modulation 
by SCOs. A) exclusion of an activated 
pseudo-exon; B) Forcing the use of an 
alternative 5’-splice site; C) exon inclusion; 
D) exclusion of a constitutive exon leading 
to an out-of-phase splicing and protein 
down-regulation. 
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pseudoexons, exclude mutated exons, exclude one or more exons for restoration of an 
open reading frame caused by a frameshift deletion, or even for downregulation 
purposes by excluding an exon leading to an out-of-phase splicing); c) blocking of ESS 
or ISS to enhance exon inclusion. 
Blocking of cryptic splicing was one of the first demonstrations for the use of AONs 
to alter splicing. This was shown in the case of β-thalassemia where mutations in intron 
1 and 2 of β-globin lead to activation of cryptic splice sites that disrupt normal splicing 
thus leading to a disrupted protein production. Targeting of an AON to the cryptic 
splice sites reverted the splicing back to normal in erythroid cells restoring β-globin 
expression (178). 
Regarding exon exclusion it is best exemplified when considering the Duchenne 
Muscular Dystrophy disease (DMD) (179). DMD is caused by deletions and non-sense 
mutations causing frame-shifts and subsequent premature termination codons leading to 
disruption of normal protein production. However deletions that maintain the reading 
frame give rise to a shorter but functional form of the dystrophin protein causing the 
milder Becker muscular dystrophy (BMD) (180). This fact was exploited in a strategy 
for DMD where by using AONs targeting consensus splice-sites or ESS, one or more 
exons, including the mutation, could be excluded thereby restoring the reading frame. 
This would then partially correct the dytrophin transcript reverting the disease to the 
milder Becker form. This strategy has been evaluated in cells and in-vivo in a DMD 
mouse model where a non-sense mutation in exon 23 leads to premature termination 
during translation. In-vivo systemic administration of AONs of different chemistries 
such as PS-2’O-Me-RNA and PMOs has led to the observation of revertant muscle 
fibers (regain of dystrophin production) in several muscle groups, body wide (181-
183). This strategy has also been used in patient-derived muscle cells in-vitro where 
targeting and induction of exon skipping was achieved for multiple exons (184,185). 
This work has subsequently led to the presentation of highly promising results from 
studies (phase 1-2a trials) in DMD patients treated locally (186,187) and, more 
recently, systemically with SSOs (188). 
As for exon inclusion, a nice example is represented by a strategy against spinal 
muscle atrophy (SMA). SMA is caused by mutations in the SMN1 gene. However, in 
humans two copies of the SMN gene are expressed (SMN1 and 2) which differ only in 
5 nucleotides, two of them present in exons. In SMN2 a translationally silent cytosine 
to thymidine exchange at position 6 of exon 7 is responsible for the skipping of exon 7 
during splicing. This results in abrogation of an ESE site (189), weakening of the 
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upstream 3’-splice site (190) and consequent exclusion of exon 7, yielding an unstable 
truncated protein, SMN∆7. Since SMN2 is similar to SMN1, if exon 7 could be 
included this would result in a functional SMN2 protein capable of compensating for 
the mutated SMN1. Hence, strategies using SSOs have been devised to achieve exon 7 
inclusion. One strategy uses the concept of competition between 5’-splice site of exon 6 
and the 3’-splice sites of exons 7 and 8, thus SSOs targeting the 3’-splice site of exon 8 
could induced an alteration in splicing pattern in favor of inclusion of exon 7 (190). In 
another strategy an exon-7-targeted SSO was linked to a peptide domain designed to 
mimic the splicing activation domains of serine-arginine–rich proteins (SR proteins). 
Similarly, another SSO contained an extra domain with a non-complementary tail with 
RNA sequences that corresponded to ESE sequences that are recognised by splicing 
proteins. These last two elegant strategies were designated by exon specific splicing 
enhancement by small chimeric effectors (ESSENCE) (191) and targeted 
oligonucleotide enhancer of splicing (TOES) (192) and both have shown successful 
inclusion of exon 7. A recent study has shown that injections of an SSO (2’-methoxy-
ethyl RNA based ON) against the intronic splicing silencer of the 5’ region of SMN2 
intron 7 into the cerebral lateral ventricles of mice resulted in an increase of SMN2 
protein and number of motor neurons in the spinal cord. In the same study intrathecal 
infusion of the SSO into cynomolgus monkeys was also performed to evaluate safety 
and tolerance of the method (193). Collectively these results give an important step in 
the direction of future clinical trials with SSOs for SMA. 
Interestingly exon exclusion has also been used as a way to achieve down-regulation 
of a specific protein. This approach was used for the knockdown of myostatin, a 
negative regulator of muscle mass, in order to improve muscle-wasting conditions 
(such as the ones encountered in DMD). Thus SSOs were designed against indentified 
ESE regions of exon 2 which, if skipped, would lead to an out-of-phase splicing 
between exon 1 and exon 3 with subsequent truncation of the open reading frame and 
transcript destabilization. The strategy was proven efficient in-vitro in C2C12 mouse 
myoblasts and in-vivo after systemic injection of the SSOs into the mouse (194). 
 It is also worth mentioning an interesting example of splice modification based on 
biasing a natural alternative splicing in favor of a specific transcript to produce a 
desired outcome. The bcl-x gene generates two isoforms by alternative splicing, the 
pro-apoptotic bcl-xS and the anti-apoptotic bcl-xL, which is overexpressed in various 
cancers (195). Alternative splicing takes place due to the usage of alternative 5’-splice 
sites in the first coding exon. Thus, an SSO targeting the 5’-splice site of bcl-xL exon II 
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was shown to redirect the splicing towards the pro-apoptotic bcl-xS (196,197). This can 
regulate cancer cell survival and sensitize them to chemotherapeutic treatments (198). 
 
1.3.4 Anti-gene 
The anti-gene strategy is based on the sequence specific targeting of the 
chromosomal dsDNA, in this way acting upstream of the antisense strategy. For this 
purpose, different types of oligonucleotides have been developed with capacity to bind 
in a sequence specific way to the major groove of the duplex, designated triplex-
forming-oligonucleotides (TFO), or to invade the duplex DNA, displacing one of the 
DNA strands. 
 
1.3.4.1 Triplex Forming Oligos (TFOs) 
The first reports on the binding of short oligonucleotides to the major groove of 
dsDNA, forming a triple-helix structure, dates back to 1987 in work done 
simultaneously by Dervan and colleagues (199) and Heléne and colleagues (200). 
However, recognition of a nucleic-acid triple structure actually came about two decades 
earlier when Poly(U) and poly(A) were found to form a stable 2:1 structure in presence 
of MgCl2 (201). 
The triple helix is formed by specific hydrogen bonding, referred to as Hoogsteen 
bonds (202), of a TFO with the polypurine sequence in a polypurine:polypyrimidine 
dsDNA motif. Binding of the TFO can be realized in two ways: parallel and anti-
parallel to the purine-binding strand. In the parallel mode (i.e. both TFO and polypurine 
strand are in the 5’→3’ direction) the TFO can bind through a TC or GT motif. With 
the parallel TC-motif the TFO forms T:A*T and C:G*C+ triplets in the Hoogsteen 
configuration. A condition for this binding is that the cytosine is protonated (C+), 
which due to the pKa of the imino group being lower than 7 makes this binding 
dependent of slight acidic conditions. With the parallel GT-motif the TFO forms C:G*G 
and T:A*T triplets also in the Hoogsteen configuration. Concerning the anti-parallel 
mode (i.e. TFO in the 3’→5’ orientation and polypurine strand in the 5’→3’ direction) 
the TFO can also bind through the GT-motif or a GA-motif. With the GT-motif the 
TFO forms C:G*G and T:A*T triplets in the reverse-Hoogsteen orientation. With the 
GA-motif the TFO forms C:G*G and T:A*A triplets also in the reverse-Hoogsteen 
orientation. 
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Figure 9. The different orientations for the three possible triplex motifs. 
 
Realization of the anti-gene strategy with the use of TFO needs, as we have seen 
above, specific targeting to polypurine:polypyrimidine rich regions. This can be seen as 
a limitation, however, such sequences have been recognized to occur quite frequently in 
almost every gene, being over-represented in promoter regions but also available in 
intronic regions (203,204). 
To achieve gene down-regulation, TFOs have been targeted to promoter regions, 
thus interfering with transcription factor binding (205,206) or formation of the initiation 
complex (207), or they have been targeted to the transcribed regions where they need to 
arrest transcription elongation (208). TFO inhibition of transcription has been described 
for some endogenous genes in in-vitro and cell culture studies. Some examples are c-
myc (209), tie1 (205), ICAM-1 (210), ets2 (206), however the efficiencies have not 
been great and there is no solid-proof in-vivo data yet for the TFO anti-gene strategy. 
This fact is probably related to some hurdles that TFOs encounter in the cellular 
environment. As such, intracellularly, the TFO needs to have the capacity to resist 
nucleases, ability to form triplexes at physiological pH, overcome charge repulsion 
between TFO and dsDNA, cope with the chromatin environment and be stable enough 
to compete with endogenous DNA binding proteins. Some of these barriers are being 
dealt with the use of modified nucleic acids in the TFOs in the same way as already 
referred to in the classical antisense strategies. 
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1.3.4.2 Duplex Invasion 
Duplex invasion associated to transcription inhibition, in the context of the 
chromosomal DNA, was first reported for a linear PNA based oligomer targeted against 
the CAG triplet repeats of the androgen receptor and TATA-binding protein genes 
(211). It was after also found to target specific c-myc regions (212,213). 
Corey and co-workers have also used linear PNA and LNA to target the 
progesterone and the androgen receptor 
genes (214-216). 
In our lab we have not been able to 
achieve transcription inhibition with linear 
PNAs or LNAs. However a new concept 
was developed using LNAs targeted to 
both the sense and antisense strand and 
where the 5’-end of one LNA oligo is 
hybridized to the 3’-end of the other. This 
formed the designated Zorro-LNA 
structure with capacity to invade the DNA duplex and having additional binding 
stability provided by the ability to hybridize to both strands (217). This construct has 
however only worked so far when two adjacent binding sites are present in the DNA 
and was only demonstrated for one sequence. 
 
 
1.4 NUCLEIC ACIDS ANALOGS 
Evolution of antisense and anti-gene gene therapy rests not only on the shoulders of 
gene delivery development but also, and quite importantly, on the shoulders of nucleic 
acid chemistry advances. While initial antisense experiments where done with 
unmodified DNA oligonucleotides it was soon realized that they needed to be made 
more efficient to achieve clinical significance. Hence, novel molecules have been 
obtained through modifications of the nucleic acids at the nucleobase, the sugar ring or 
phosphodiester backbone. They have been designed with the objective to improve 
certain properties such as the process of synthesis, nuclease resistance (resistance to 
degradation), affinity and selectivity towards other nucleic acids (mostly regarding 
binding kinetics to RNA or DNA), and in some cases even the ability to cross 
biological membranes. 
Figure 10: Schematic representation of 
the Zorro-LNA concept. Two LNA rich 
oligonucleotides (in red) are hybridized 
simultaneously to the sense and antisense 
strand. The oligos can be interconnected 
by a linker region (in blue) composed by 
nucleotides or other chemistries (eg. PEG). 
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For the purposes of this thesis only the modifications most generalized in the 
antisense field will be covered with focus on PNAs and LNAs. 
Among the first modifications made to nucleic acids was an alteration to the 
phosphodiester backbone where one of the non-bridging phosphate oxygen atoms is 
replaced with a sulfur atom. These phophorothioate containing oligonucleotides (first 
generation PS-ONs) were mainly thought to increase the stability against nucleolytic 
degradation (218). However, they also improve the pharmacokinetic properties of the 
oligonucleotides, when used systemically, by increasing the persistence time in 
circulation as a result of the binding to serum proteins, which prevents rapid renal 
excretion (219). However, this latter property is connected to a recognized tendency of 
PS-ONs to unspecifically bind to proteins which can provoke toxicity effects (219). 
They also have a reduced affinity towards complementary RNA in comparison to 
unmodified DNA (220). 
Nonetheless their advantages over the completely unmodified DNA have granted 
PS-oligos with the longest history in clinical tests with most of the advanced studies 
being performed with this modified ON. 
Accordingly, and as already mentioned, the only AON approved by the FDA to date 
is the 21-mer phosphorothioate Vitravene (fomivirsen) (161). Two additional PS-
AONs, Genasense (221), and Affinitak (222), have reached advanced stages of clinical 
trials against cancer, targeting Bcl-2 and PKC-α, respectively. The results of the 
clinical trials were however disappointing (223,224). 
To overcome some of the PS limitations a new generation of nucleic acid 
modifications emerged. The second generation ONs were focused on increasing the 
binding affinity and reducing toxicity effects. These nucleic acids had modifications on 
their 2’-O positions and the most preeminent were the 2’-O-methyl (225) and 2’-O-
methoxy-ethyl (MOE) (226) RNAs. These modifications confer a much less affinity 
towards proteins, however, a drawback of fully modified 2’-O-Me or MOE AONs is 
their inability to activate the RNase H mechanism. This problem has been tackled by 
the introduction of the gapmer concept already discussed previously. 
These modifications conferred nuclease resistance, however, when AONs are 
additionally modified with PS this results in further improvements. MOE-AONs have 
been more widely used than 2’-O-methyl-AONs and are currently under evaluation in 
clinical trials, some examples being the targeting of apolipoprotein B-100 for the 
potential treatment of hypercholesterolemia (227) and targeting of alpha 4 integrin 
(VLA-4) for treatment of multiple sclerosis (228,229). 
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Over the years a variety of other nucleic acid modifications have been derived, again 
driven by the premises of increased affinity and improved stability. Thus, the concept 
of conformational restriction has been applied as well as completely different chemical 
moieties substituting the furanose ring have been developed. In analogy to the previous 
first/second-generation terms these have been designated by third-generation 
modifications or 3rd Gen-AONs. Included are Locked Nucleic Acids (LNA), Peptide 
Nucleic Acids (PNA), and morpholinos (PMO). 
Morpholinos were developed in the late 80’s and they were seen as a solution to the 
production costs of existing DNA analogues (230). They used less expensive 
ribonucleosides and the synthesis steps did not involve expensive catalysts and 
postcoupling oxidation steps. A morpholino is a non-charged DNA analog, in which 
the ribose is replaced by a morpholino moiety and phosphoroamidate intersubunit 
linkages are used instead of phosphodiester bonds. Both the constrained ring unit and 
the non-ionic character make morpholino-RNA duplexes more stable than DNA-RNA 
duplexes. A fully modified PMO oligomer does not elicit RNase H, they have been 
nevertheless quite successfully used in steric blocking mechanisms in the field of splice 
correction, the most preeminent example being their use in the DMD scenario (66,231), 
and for knocking out viral gene expression and replication by translational arrest 
(232,233). PNA and LNA are discussed in more detail in the sections below. 
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Figure 11. The basic nucleic acids and examples of modifications used in antisense 
oligonucleotides. 
First generation involved the modification of the phosphate backbone by substitution of a non-
bridging oxygen by sulfur atom; Second generation involved modifications at the 2’-O position; 
Third generation is more broad involving modifications restricting the sugar ring conformations 
and complete substitutions of the furanose ring. 
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1.4.1 PNA 
PNA was developed by Ole Buchardt and co-workers in the 80’s (234). It is a 
nucleic acid analog composed of repeated N-(2-aminoethyl)glycine units with the 
nucleobases attached to the glycine nitrogen via a methylenecarbonyl linker (235). The 
nature of the backbone-resembling amino-acid linkages confers to the molecule a 
neutral charge in comparison to the intrinsic negative charge of nucleic acids provided 
by their phosphate linkage backbone. 
PNA molecules have the ability to bind to complementary DNA or RNA 
oligonucleotides through Watson-Crick base paring (236). Due to the lack of 
electrostatic repulsions between PNA-DNA hybrids, the thermal stability (measured as 
melting temperatures, Tm) of such duplexes is virtually independent of ionic strength 
and in general higher than the corresponding DNA-DNA hybrid. 
PNA has also the capacity to strand-invade a dsDNA, forming very stable 
(PNA)2/DNA triplex structures with homopurine sequences and where the non-
complementary DNA strand remains as a loose loop structure (237). In this mode of 
binding one strand of PNA binds via Watson-Crick base pairing while the other binds 
the same strand via Hoogsteen interactions. This strand-invasion capacity is further 
enhanced when two pyrimidine PNAs are connected through a flexible linker forming a 
bisPNA (PNA clamp) molecule. 
PNA oligomers have also been found to be very stable in human serum and cellular 
extracts, being resistant to nuclease and protease degradation (238). 
These PNA properties have made them useful as antisense and anti-gene molecules. In-
vitro cell-free experiments have shown that PNA leads to inhibition of transcription 
initiation as well as elongation, especially when positioned on the template strand, and 
also translational block has been observed (239-241). 
A drawback associated with the use of PNA is their lack of cellular uptake, which 
has hampered its development into a therapeutic option. However, PNAs can be 
conjugated with peptides increasing their membrane permeability (242). Such PNA-
peptide conjugates have been used as anti-gene agents targeting transcriptional start 
sites in the progesterone receptor gene in cells. Inhibition of transcription was achieved 
when PNA was used at high ratios to the target site (215). PNA-peptide conjugates 
have also been used as splice switching oligos (SSOs) (243-245). 
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1.4.2 LNA 
LNA is a nucleic acid analog containing a bridging methylene carbon between the 2’ 
and 4’ positions of the ribose ring. This bridge leads to a conformational restriction 
(C3’-endo) which pre-organizes the LNA monomers in an N-type conformation (246-
248). 
If a DNA or RNA oligonucleotide has some of its monomers substituted by LNA 
this will push the nucleotides flanking the LNA bases into a N-type conformation 
(especially the nucleotides following the LNA in the 3’ direction). As such, a partially 
LNA modified oligo will have its phosphate backbone pre-organized due to the C3’-
endo locked conformation. This in turn leads to a decrease of entropy upon duplex 
formation while contributing to a more efficient stacking of the nucleobases (increased 
loss of enthalpy upon duplex formation) (249). In conclusion an LNA-DNA or LNA-
RNA duplex will have much higher Tm then their homodimer counterparts due to 
favorable enthalpy and entrophy effects. Worth noting is that an LNA-RNA duplex can 
have a slightly higher binding affinity than a corresponding LNA-DNA duplex. This is 
also explained in part by the RNA-like conformation imparted by the locked sugar 
moiety both in the single stranded and duplex state. While a DNA-DNA duplex has a 
B-form helix structure, RNA-RNA duplexes have an A-form structure and DNA-RNA 
duplexes are in an intermediate state between A- and B-forms. LNA modifications 
impose an A-type geometry (due to their locked N-type conformation), thus they 
slightly favor duplex formation with RNA strands (250). 
These LNA properties conferring high affinity and sequence specificity makes them 
an excellent nano-technological tool for creating self-assembling nano-structures. 
Moreover, they have other useful properties, such as an enhanced serum stability (251) 
a slower plasma and renal clearance (252) as well as signs of low toxicity (252,253), 
that gives them a high therapeutic potential. 
In the antisense field LNAs have been used quite successfully, especially when 
integrated into gap-mer designs. They have proven to be efficient in in-vivo settings 
when targeting apolipoprotein-B in the liver of mice and non-human primates (254) 
and as anticancer agents targeted to survivin (255), which is currently being evaluated 
in phase I clinical trials (256). 
Interestingly LNAs have also been used to improve the biological efficiency of 
siRNAs by the introduction of LNA monomers in both strands of siRNA. LNA 
substitution should be kept to a minimum and out of the central region of the RNA 
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(257). They were also found to alter strand-bias through selectively increasing the 
affinity of the closing base-pair at the 5’-end of the siRNA sense strand (258). 
In the anti-gene field LNA has been used to modify TFOs. LNA substituted TFOs 
have an increased triplex thermostability although a fully LNA substituted TFO 
hampers triplex stability (259). Moreover, increased affinities are also seen at neutral 
pH, which is important for the TFO parallel motif  (homopyrimidine-type TFOs) and 
for the efficient binding in cellular conditions (260-262). 
Linear LNAs have been used by Corey’s group to arrest transcription of the 
androgen and progesterone receptor genes (216). 
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2 AIMS 
The aims of this Ph.D studies were to further develop the potential of nucleic acids for 
gene delivery and gene regulation with focus on the following areas: 
 
I- Improving the capacity for nuclear import of exogenous nucleic acids; 
 
II- Develop new and efficient cell delivery methods for oligonucletide-based 
strategies; 
 
III- Develop nucleic-acids/oligonucleotides as a new splice-correction 
therapeutic option for XLA; 
 
IV- Further develop an anti-gene strategy based on the use of LNA-modified 
oligonucleotides and study the concept of bisLNAs. 
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3 METHODOLOGY 
 
This section covers some relevant methods used in this thesis papers. 
3.1 PREPARATION OF STREPTAVIDIN-OLIGONUCLEOTIDE 
COMPLEXES 
Streptavidin-Alexa488 (Molecular Probes) + biotinylated oligonucleotide constructs 
were formed by incubating 3µg STV (Streptavidin) reconstituted in 1x phosphate 
buffer saline (PBS, pH 7.4) with 2-4 times molar amount of biotinylated oligo 
constructs. The volume was adjusted with nuclease free water (Qiagen) to have a final 
concentration of 329ng STV/µl and the incubation proceeded for 2h at r.t. and if not 
used the same day the constructs were stored at 4°C. 
 
3.2 XENOPUS OOCYTE MICROINJECTIONS, NUCLEAR DISSECTION 
AND FLUORESCENCE MICROSCOPY 
The Xenopus oocyte offers excellent conditions for the study of nucleo-cytoplasmic 
transport of different materials (synthetic or biological) and has been previously used 
for early studies on nuclear transport of karyophilic proteins and U-snRNAs (263,264). 
They are easy to microinject and retain the nuclear membrane integrity throughout the 
experiment, moreover the nucleus is relatively easy to isolate and analyze due to its 
size. 
 
Prior to microinjections the prepared STV-oligo constructs were spun down at 16,000 
xg for 5 minutes. A volume of 41.4nl of STV-oligo constructs were injected in the 
cytoplasm of the oocyte using the Nanoinjector 2000™ pump (World Precision 
Instruments, Inc) followed by incubation at 19°C in OR2 buffer for 4h. After 
incubation, oocyte nuclei were manually dissected with metal tweezers in nuclear 
dissection buffer (140mM KCl; 0.5mM MgSO4; 20mM Tris-HCl pH 7.2) and further 
processed for either western blot or fluorescence microscopy. For microscopy the 
oocytes were placed in a petri dish filled with nuclear dissection buffer, manually 
dissected and immediately imaged. Visible light and fluorescent photos were taken 
with the use of a Stereo microscope Leica MZ6 equipped with a Leica stereofluorescent 
module and a Leica Video/photo tube to which was attached a Canon powershot S40 
Camera. Photos were captured using the program Canon remote capture version 
2.5.1.11. 
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3.3 TRANSFECTIONS OF STREPTAVIDIN-OLIGO COMPLEXES 
In order to easily introduce Streptavidin-oligonucleotide conjugates into mammalian 
cells a method for the intracellular delivery of proteins was used based on creation of 
protein delivery complexes with a cationic amphiphile molecule (PULSin reagent). 
This allowed us to use an easy transfection-like based method instead of performing 
cell-by-cell microinjections. 
U2OS cells were seeded on top of coverslips in a 24-well plate with DMEM+10% FCS 
the day before transfection so that they were confluent or close to confluency the next 
day. Streptavidin-Alexa488 (Molecular Probes) + oligonucleotide constructs (Figure 2) 
were formed by incubating 2µg STV (Streptavidin) reconstituted in 1xPBS (pH 7.4) 
buffer with 2-4 times molar amount of biotinylated oligo constructs for 2h at r.t. 20mM 
Hepes buffer (pH 7.4) was then used to bring the total volume up to 100µl and then 
3.5µl of PULSin transfection reagent (PolyPlus-Transfection, New York, USA) was 
added. The mixture was vortexed and left to incubate for 15min at r.t. During this 
incubation time the cells were washed twice with PBS and 900µl of pre-warmed OPTI-
mem I (Invitrogen) was added to the wells. The PULSin complexes were then added to 
the cells and left to incubate for 4h. Subsequently the medium was discarded and the 
cells washed twice with pre-warmed OPTI-MEM I. Finally, 400µl of OPTI-MEM I 
was added to the wells after which the cells were further incubated for 2-3h. Cells were 
then analysed by fluorescence microscopy and confocal microscopy. 
 
3.4 HELA/LUC705 SPLICE CORRECTION ASSAY 
This splice correction assay uses a HeLa cell line clone stably expressing a luciferase 
transcript interrupted by a mutated b-globin intron (HeLa/Luc705 system)(88). The 
mutation creates an aberrant 5’ splice site while activating an upstream 3’ cryptic splice 
site. This leads to production of a non-functional luciferase mRNA containing a 
fragment of the original intron due to the defective splicing. By introduction of a 
validated antisense oligonucleotide against the mutation site on the pre-mRNA, the 
splice mechanism is redirected to its normal pattern by the simple steric block due to 
the hybridization of the oligo with the pre-mRNA. This allows the production of 
correct Luciferase which can be easily measured by testing for the enzyme activity or 
using RT-PCR to detect corrected Luc mRNA transcripts. The method is widely used 
to test for the efficiency of new oligonucleotide transfection reagents. 
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3.5 SEMI-QUANTITATIVE RT(REVERSE-TRANSCRIPTION)-PCR FOR 
DETECTION OF SPLICE CORRECTION 
This is a semi-quantitative technique to verify the amount of splice-corrected mRNAs 
in relation to the non-corrected mRNAs. The different splicing patterns obtained are 
differentiated as bands of distinct sizes in agarose gels. For this a set of PCR primers 
need to be designed flanking the RNA sequence that is going to be affected by the 
splice pattern modifications, in our case, induced by the oligonucleotide treatments. It 
was used for the relative quantification of Luciferase (paper I, II and III), dystrophin 
(paper II) and Btk (paper III) spliced transcripts. 
 
3.6 PHYSICAL CHARACTERIZATION: DYNAMIC LIGHT SCATTERING 
AND ZETA POTENTIAL STUDIES 
Dynamic Light scattering (DLS) is a technique for measuring the size distribution 
profile of particles in solution. Particle size is determined from fluctuations in scattered 
light intensity due to the Brownian movement of the particles (265). Zeta potential is 
related to the surface charge of a particle in simple systems and can be affected by 
changes in the environment (pH, salt, adsorption of proteins). It provides information 
about possible charge interactions of the particle with, in the case of gene/drug delivery 
systems, cellular surfaces or biological fluids such as when the particle is injected in the 
blood system. 
 
3.7 FLUOROMETRY 
In paper II a method based on the fluorescence detection of Cy5-labeled 
oligonucleotides was used to quantify the total amount of oligonucleotide efficiently 
taken up by cells in-vitro. This method uses a standard curve based on the fluorescence 
emission of known amounts of Cy5-oligonucleotides to quantify the amount of 
oligonucleotide internalized by the cells after the transfection with the oligo-complexes. 
The cells are washed and lysed to release the oligonucleotide after which the 
fluorescence emission from the lysate is measured using a fluorescence reader. 
 
3.8 FLOW CYTOMETRY 
Flow cytometry is a technique for the simultaneous multiparametric analysis of 
physical and chemical cell characteristics. It is based on light scattering but also allows 
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fluorescence detection from single cells. Flow cytometry allows the high-throughput 
analysis and quantification of different parameters. 
Flow cytometry was used in paper II for analysis of single-cell transfection efficiencies 
based on the detection of cellular internalization of a fluorescent oligonucleotide, and 
used in paper II for analysis of expression of Btk protein after intracellular staining with 
a fluorescent antibody marker. 
 
3.9 STABILITY STUDIES 
In paper II stability studies of PF14-oligo complexes are done using incubations for 
relatively long periods of time (8 weeks) at temperatures of 40ºC and 60ºC. After this 
time the complexes are used in a transfection experiment to access their efficiency. 
Storage at high temperatures increases the rate of degradation mimicking reactions that 
could take years to occur (266). For this reason this method is routinely used to assess 
the long-term stability of formulations (267). 
 
3.10 ISOLATION OF PRIMARY MOUSE B-LYMPHOCYTES 
Spleens from BTKmut/BAC mice and wild-type (C57BL/6 strain) were collected and 
B-lymphocytes purified using an EasySep® mouse B-cell enrichment kit through 
negative selection (StemCell Technologies). The purity of isolated B-lymphocytes was 
checked by staining of the cell population with a PE-anti-mouse CD19 (BD 
Pharmingen) and analysed by FACS. Purity levels were always above 90%. During the 
experimental procedures B-lymphocytes were maintained in culture using the medium 
IMDM with 15% FCS and supplemented with 50µM β-mercaptoethanol. 
 
3.11 CELL ELECTROPORATIONS 
The electroporation technique uses a short externally applied electrical field to cells in 
suspension in order to increase the electrical conductivity and permeability of the cell 
plasma membrane. This enables the access of foreign material (proteins, DNA) to the 
intracellular environment and even to the nucleus. This method is very useful when 
dealing with in-vitro transfections of primary cells, which are known to be quite 
difficult to transfect using common delivery reagents (eg. lipid and polymer based 
reagents). Electroporation was used in paper III for transfection of primary human 
monocytes and primary mouse B-lymphocytes with oligonucleotides. 
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3.12 AGAROSE GEL ELECTROPHORESIS FLUORESCENT BINDING 
ASSAY (GEFA) 
This assay was set-up in order to detect and quantify fluorescently labeled 
oligonucleotides hybridized/bound to plasmid DNA. By running an hybridized plasmid 
in an agarose gel the smaller free oligonucleotides can be separated from the bigger 
plasmid DNA. The fluorescent signal coming from the plasmid DNA band (due to the 
bound oligos) can then be quantified by using a standard curve of known amounts of 
fluorescently-labeled oligonucleotides run in the same agarose gel in the same 
conditions. This quantification cannot however be regarded as 100% accurate since the 
environment in close proximity can influence fluorescent labels. Thus, a fluorescent 
label in an oligonucleotide hybridized to plasmid DNA is surrounded by negative 
charges and in close proximity to the double-stranded DNA phosphate backbone. This 
could be different from the standard curve conditions used where the oligos are at most 
hybridized to a complementary single-stranded oligonucleotide. We cannot exclude 
that this different environment might affect the fluorescent label properties. 
Nevertheless this method of quantification can be seen as a good approximation. 
 
3.13 S1 NUCLEASE DIGESTION ASSAY 
The S1 digestion assay provides a way to verify and quantify the double-strand 
invasion capacity of an oligonucleotide. S1 nuclease preferentially cuts single-stranded 
DNA. Hybridization of an oligonucleotide with dsDNA by means of duplex invasion 
leads to the displacement of one of the DNA strands. This now single stranded region 
of DNA will be accessible for S1 digestion which will create a nick in the plasmid 
DNA and loss of supercoilness. By quantifying the amount of supercoiled and nicked 
plasmid it is possible to determine the efficiency of the duplex invasion/hybridization 
of the oligonucleotide in question. 
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4 RESULTS, DISCUSSION AND PERSPECTIVES 
 
4.1 PAPER I 
A synthetic snRNA m3G-CAP enhances nuclear delivery of exogenous proteins 
and nucleic acids 
The objective of this study was to develop an alternative to the NLS peptide based 
nuclear delivery strategies for nucleic-acids and non-viral vectors. We reasoned that the 
high density of positive charges usually found in NLS peptides can be of problem when 
these peptides are used in conjunction with DNA for the purposes of improved nuclear 
uptake. Thus, a strong association of the positively charged NLS with the negatively 
charged DNA phosphate backbone could result in at least a partial blocking to the 
recognition of the NLS by the transport receptor proteins (importins). We therefore 
decided to explore the use of a different type of NLS signal entirely based on a nucleic-
acid structure found in the 5’-end of endogenous U snRNAs. The hypermethylated 5’-
cap structure, 2,2,7-trimethylguanosine-cap (m3G-CAP), acts as a signal for the nuclear 
import of fully assembled U-snRNPs where they will function in the splicing 
mechanisms. 
We developed a completely synthetic m3G-CAP which we could couple to 
oligoribonucleotides, and established systems for assessing its effect on the nuclear 
import of non-permeable cargoes across the intact nuclear membrane. The systems 
were based on the coupling of biotinylated capped-oligos to a fluorescent streptavidin. 
This created a construct with MW over 60KDa which is above the nuclear permeability 
cut-off. We then analysed the nuclear import capacity in Xenopus oocytes using 
microinjections. The usefulness of this system rests on the fact that the oocyte being a 
non-dividing cell maintains the nuclear membrane integrity throughout the course of 
the experiments. In addition, it is relatively easy to microinject and analysis of the 
uptake of fluorescently labeled streptavidin in the oocyte nucleus is fairly 
straightforward. Using this system we observed a marked fluorescence coming from 
the nucleus of oocytes injected with CAP-containing streptavidin in opposition to no 
fluorescence in non-capped streptavidin. We also used a mammalian cell system based 
on the delivery of streptavidin into cells and localization of the constructs using epi-
fluorescent and confocal microscopy, again revealing the efficiency of the m3G-CAP in 
supporting the nuclear delivery of non-permeating molecules. 
  43 
Additionally, we used a splice correction assay based on the HeLa/Luc705 system 
(88) to test our CAP signal in a functional assay. Since the splicing mechanism only 
occurs in the nucleus we wanted to test if splice-correcting oligonucleotides equipped 
with the nuclear transport entity could have an advantage over oligonucleotides not 
equipped with the transport system. Indeed, although the correction levels were low we 
observed a significant increase of around 3-4 fold in splice correction efficiency. 
Although we employed short oligos in this last assay, and diffusion is in principle still 
possible through the nuclear pores, we believe that in suboptimal conditions, such as 
low transfection efficiencies or less efficient oligos, higher intranuclear concentrations 
should be beneficial. It is also important to note that, in-vitro, very high intracellular 
concentrations can be easily achieved using transfection reagents, whereas in-vivo, in a 
clinical context, intracellular oligonucleotides levels may be a limiting factor. 
It should be noted that these results were achieved using a less efficient oligo based 
on a non-phosphorothioated 2’-O-methyl RNA oligo in part due to the inability to 
conjugate and purify in a satisfactory way PS-based CAP-oligos. Nonetheless, owing to 
some toxicity that is attributed to PS-based oligonucleotides, due to for example 
nonspecific protein binding (268,269), it is feasible to think that new nucleic acid 
chemistries can abolish the need in the future for the PS modification. This however 
does not preclude the development of new synthesis options that will allow the capping 
of PS-oligos, which are under development at the moment. 
Another important issue is the fact that for in-vivo applications the CAP structure 
will most likely need to be modified to better withstand degradation conditions in 
serum and inside the cell. Triphosphate linkages are most likely easily degraded if 
completely exposed to extra-cellular environments, additionally, inside the cell there 
are de-capping enzymes, such as Dcp2 (270), that could influence the half-life of the 
CAP. Therefore, developing CAP analogues with improved degradation resistance is of 
uttermost importance for future in-vivo applications of the CAP concept. 
Besides its use in oligonucleotide delivery the CAP structure can be used as integral 
part of a plasmid DNA delivery vector. The most obvious choice for us would be to 
integrate it in a system developed in our lab where one can easily attach different 
functional entities to plasmid DNA, via hybridization of PNA or LNA anchors (271). 
Being negatively charged as the DNA, any unspecific electrostatic interactions that 
happen when using the classical NLS peptides are not relevant for the CAP, which can 
then be totally available for interaction with its specific import receptor. 
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4.2 PAPER II 
PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in 
solution and as solid formulation 
 
The most commonly used oligonucleotides, such as DNA/RNA, PNA, LNA, PMO 
based, have in general low membrane penetration and cellular uptake. This fact made 
the development of methods to enhance their cellular internalization of uttermost 
importance so that not only the therapeutic but also the biological-tool potential of 
nucleic-acids could be realized. 
In this paper we have developed a new cell penetrating peptide as a delivery vector 
for PS-2’-O-methyl-RNA splice correcting oligos, employing a non-covalent 
complexation strategy. CPPs have been recognized for their capacity to deliver several 
cargoes to cells both in-vitro and in-vivo with quite low toxicities associated (272). 
CPP-cargo complexes are thought to internalize preferentially by endocytosis 
mechanisms, however one limitation has been their rather extensive entrapment inside 
endosomal vesicles (273). 
The employed CPP builds on previous peptide modifications, such as stearylation, 
which was shown to increase complexation and endosomal release. Previous 
transfection efficiencies with stearyl-TP10 (274) and stearyl-(RxR)4 (275) were 
however somewhat lower than with Lipofectamine 2000 besides being affected by 
serum proteins. Thus, the developed CPP was based on the previous stearylated TP10 
but modifying lysines and isoleucines for ornithines and leucines, respectively. The 
reasoning behind the exchange for ornithines was based on earlier reports showing that 
poly-L-ornithine demonstrated superior transfection efficiency (up to 10-fold) 
compared to equivalent poly-L-lysine-based systems. This increase in efficiency was 
related to the higher affinity for DNA and the ability to make more stable complexes at 
lower charge ratios (276). Furthermore, it was hypothesized that ornithine, being a 
nonstandard amino acid, would be less prone to serum proteases, and thus could retain 
activity in serum conditions. 
The new CPP, PF14, was initially used for delivery of a SCO in a splice correction 
reporter system, HeLa/Luc705 (already described in paper I). The efficiency of 
delivery, correlated to luciferase correction and gain in enzyme activity, was higher 
than for Lipfectamine 2000 when transfections were made both without and with 
serum. PF14-SCO complexes were also shown to be efficient for exon skipping in 
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differentiated mdx mouse myotubes which carry a point mutation in exon 23 of the 
dystrophin gene. 
Uptake of PF14-SCO complexes was attributed to processes of endocytosis. 
Transfections done in presence of chloroquine showed an increase in the splice-
correction activity, while SCO uptake remained nearly unchanged. This discrepancy 
between uptake and biological activity in the presence of chloroquine, a well-known 
endosomolytic agent, suggests the involvement of endocytic vesicles in the uptake of 
the nanocomplexes. Importantly, live cell confocal imaging confirmed this results since 
the nanocomplexes extensively colocalized with labeled dextran, a marker for fluid-
phase endocytosis. The nanocomplexes were characterized in terms of size giving an 
average of 300-400nm and surface Zeta potential which had a negative value. The 
negative surface potential raises some interesting questions in terms of the exact 
mechanism of interaction with the cell membrane and the mechanism of uptake. In fact 
the cell membrane negative potential could in principle pose an obstacle to the 
interaction of another negatively charged particle, due to electrostatic hindrance. There 
are however reports on other types of nanocomplexes, based on gold nanoparticles, 
which have an increased efficiency in uptake depending on their negative potential and 
the amount of oligonucleotide load they carry. This uptake was hypothesized to depend 
on the adsorption of specific proteins to the surface of the nanoparticle (277). Other 
reports have also shown that cationic liposome and plasmid DNA complexes are 
negatively charged under optimal transfection conditions (278,279). A more detailed 
study on the uptake mechanism of the PF14-SCO complexes is perhaps warranted in 
light of these facts. 
Another interesting property of the PF14-SCO complexes is the possibility to form 
solid formulations using a solid dispersion technique based on solvent evaporation (in 
this case water) by speed drying under elevated temperature (55–60ºC) and reduced 
pressure. The solid dispersion complexes almost completely retained the same activity 
as freshly prepared complexes in a splice-correction-assay. The success of the solid 
dispersion was dependent on the type and amount of excipient used, with 3.33% of 
lactose being the best condition. 
The possibility of forming efficient solid formulations is of course a step towards the 
direction of having an oral drug delivery system. 
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4.3 PAPER III 
Correction of BTK splicing mutations in X-linked agammaglobulinema (XLA) by 
an exon-skipping strategy 
 
In this manuscript our objective was to design splice correction oligonucleotides 
(SCOs) to correct a BTK splicing defect deriving from a mutation in the intron 4 of the 
gene. It was previously identified in our group a specific A→T mutation in intron 4 of 
the BTK gene which creates a novel splice donor site. This, together with a pre-existing 
cryptic splice acceptor site in the same intron 4, results in the addition of a pseudo-exon 
sequence of 109bp between exons 4 and 5 (280). This specific aberrant splicing event 
completely abolishes BTK protein production. 
The inclusion of this pseudo-exon due to the aberrant splicing suggested that exon 
skipping with the use of splice-correcting ONs could be considered as a treatment 
option for this XLA scenario. 
We decided to establish an in-vivo model for this BTK aberrant splice and for that it 
was created a BAC (bacterial artificial chromosome) transgenic mouse harbouring the 
full human BTK locus with the referred point mutation. The transgenic mouse was 
confirmed to express the aberrant BTK pre-mRNA in B-lymphocytes. 
The strategy was to exon-skip the created pseudo-exon in intron 4 by redirecting the 
splicing to the proper 5’- and 3’-splice sites. Initially, we used a model cell line 
expressing a Luciferase gene interrupted by the mutated BTK intron 4. We tested a 
number of different PS-2’-O-methyl RNA AONs to distinct sites including the aberrant 
5’- and 3’-splice sites and also several exonic splice enhancer sites (ESE) in the formed 
pseudo-exon. The ESEs were identified using different published bioinformatic 
algorithms (281-283). The initial screening allowed the identification of the most 
promising oligos which were then designed as LNA modified 2’-O-methyl RNAs in 
order to increase their potency, and in preparation for future in-vivo studies where 
LNAs have been quite successful in other applications (252,254,255,284). The LNAs 
proved to be quite efficient in the model cell line. 
We confirmed the efficiency of our LNA-SCO by initially using monocyte cells 
purified from an XLA patient bearing the BTK intron 4 mutation. Monocytes express 
BTK but do not need it for their development and survival. Thus using ex-vivo 
transfections we observed correction of BTK transcript and restoration of protein 
production to some extent. These results confirmed that the splice correction strategy 
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was working not only in our luciferase model system but also in the context of the full 
human BTK gene. 
Importantly, ex-vivo transfections of purified BAC transgenic mouse B-cells with 
the LNA-SCOs showed that splice correction was also efficient in the context of B-
lymphocytes. We obtained correction at the level of the BTK mRNA and also protein 
production. To our knowledge this is the first BAC mouse model of a splicing mutation 
in a full human gene. 
In terms of a future therapeutic application two strategies could be possible. One 
alternative could be an ex-vivo approach in which case the pro-pre B-lymphocyte 
population could be mobilized, collected and transfected with the SCOs. After this step 
the cells could be re-infused and by regaining BTK production the developmental steps 
could be completed. A particularly attractive feature of XLA is the fact that the most 
mature cells of the B-cell lineage, the plasma cells, do not express BTK protein, and 
hence are not dependent on this signal transducer for their survival. This means that if 
immature primary B-cells expressing BTK can be generated following SCO treatment, 
upon immunization these cells could mature into long-lived plasma cells, which could 
confer protection far beyond the actual treatment period. Owing to that there are 
efficient vaccines available for bacterial agents such as Hemophilus influenzae and 
pneumococci, important pathogens for XLA patients, this could potentially have a great 
impact. 
The other alternative is the in-vivo delivery of the SCOs. BTK mutations leading to 
loss of protein production lead to a developmental block of B-cells at the pro-pre B-cell 
stage leaving the patients with a severe systemic B-lymphocyte defect. Thus, SCOs 
would need to be accumulated in the bone marrow, where B-lymphocyte development 
takes place, and be taken up by pro-pre B-lymphocytes or earlier progenitor cells in the 
developmental ladder. Immunization would then be the course of action to follow as in 
the ex-vivo approach. 
 
4.4 PAPER IV 
Optimization of bis-LNA for supercoiled DNA binding and duplex invasion 
 
This work is in line with earlier publications from our lab discussing the anti-gene 
properties of LNA based oligonucleotides designated Zorro-LNA (217,285). Our 
earlier reports indicated that for successful double-strand invasion two adjacent binding 
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sites were needed, whereas with one site binding was severely reduced. Moreover we 
have previously observed that linear LNAs were binding only to supercoiled plasmid 
DNA (which have a negative helical twist) and upon linearization of the plasmid DNA 
the binding would be lost, by a “kick-out” effect (286). 
In consequence, we decided to investigate the design and use of a clamp-type of 
LNA (designated by bisLNA in analogy to bisPNA), to suppress the earlier identified 
limitations. The bisLNA was composed of a TFO unit (binding in the major groove by 
Hoogsteen interactions) and a DNA linker to the Watson-Crick binding unit.  We first 
tested the influence of LNA modifications on each arm of the bis-construct. This was 
done using a quite short construct binding to 6 adjacent 10mer-sites introduced in a 
plasmid DNA. The following constructs were tested [TFO(arm)-WatsonCrick(arm)]: 
DNA-DNA; LNA-DNA; DNA-LNA; LNA-LNA. The degree of LNA modifications in 
each arm was always 50% since it was known from before that consecutive LNA bases 
impart an extreme rigidity to a TFO resulting in less binding efficiency (259,287). The 
results showed a major influence of having both arms modified with the LNA bases. In 
addition we also verified that while incubations with either TFO-arm or WC-arm alone 
did not produce any quantifiable binding, when incubating the separate arms together 
some level of binding was regained. This suggests that the increased binding/duplex 
invasion is possibly not only due to the local increase of concentration when TFO and 
Watson-Crick arms are linked together, but could also be attributed to local 
conformation changes on the target DNA-strand imparted by the LNA-modified TFO 
or duplex binding domains. It is conceivable that a possible pre-organization of the 
whole LNA•DNA:LNA structure into an A-type helix has a positive effect both for the 
triplex LNA strand and duplex LNA strand binding, since both preferably bind to, or 
induce, the A-type or A-type “like” helix. 
Importantly, we verified that after successfully binding to plasmid DNA the bisLNA 
withstands some degree of linearization of the plasmid by restriction enzyme digestion. 
This result showed for the first time an LNA based construct capable of resisting the 
“kick-out” effect when the negative helical twist is lost from duplex DNA. 
We went on to test a bisLNA design that could in fact bind to a single target site. 
The previous 10-mer bisLNA was unable to bind to a single site plasmid which was not 
so unexpected due to the low Tm values calculated for the Watson-Crick arm of the 
bisLNA (around 30°C according to calculations done using LNA Oligo Prediction 
Tools at http://www.exiqon.com/oligo-tools). Hence we designed a longer bisLNA 
with 15 bases in each arm, and a tail-clamp type of bisLNA with a 29 bases WC-arm 
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and a 15 bases TFO-arm. The results obtained for the duplex invasion capacity of these 
oligos showed a low binding for the 15-15 bisLNA, however when the tail-clamp (29-
15) bisLNA was used we managed to achieve around 50% binding in close to 
physiological conditions (intranuclear salt concentrations and pH 7.3). When the 
incubation time was increased from 24h to 72h there was a further increase in binding. 
The tail-clamp LNA, despite the high percentage of LNA modification and the large 
size (29-mer for the duplex arm and additional 15-mer for the TFO arm) still showed a 
decent discrimination against a site with one point mutation, since binding efficiency 
was reduced quite significantly (close to 10 fold less binding efficiency). 
We believe that in a cellular and genomic context the bisLNA might prove to have 
advantageous properties. These can come from the increased affinities towards negative 
supercoiled dsDNA under intranuclear salt and pH conditions, which would allow to 
better withstand the competition from DNA binding proteins, especially regarding the 
TFO domain. Moreover, and when comparing to the ssLNA strategies used thus far, the 
bisLNA has the advantage of being able to more efficiently scan the genomic sequence 
through the TFO domain. This domain provides the capacity of binding, much like 
dsDNA binding proteins, on the outside of the duplex through major groove 
interactions, thereby correctly positioning and locally increasing the concentration of 
the Watson-Crick bisLNA arm (duplex domain) for a more efficient double-strand 
invasion of the duplex genomic DNA. 
Some points remain to be investigated and optimized since although we indeed for 
the first time achieve significant binding to a single site in close to physiological 
conditions the concentrations still remain high. It will be interesting to investigate the 
reason for the big difference seen between the bisLNA with and without the tail clamp. 
The melting temperatures (Tm) for the WC binding arms are expected to be already 
quite high for both constructs so other mechanisms or structural features could be 
playing a role in the increased binding seen for the tail-clamp bisLNA. Also, if the tail-
clamp is an essential feature it would be interesting to see what would be the minimum 
size still giving significant binding. To increase the binding affinity, new LNA-based 
modifications (eg. functionalized 2’-amino-LNAs (288)) or mixed chemistries can be 
employed [such as intercalator units, eg. Twisted-Intercalating Nucleic Acids-TINA 
(289)]. In addition, it would be worthwhile to see if the bisLNA design can be 
integrated in the ZorroLNA construct in order to increase its binding affinity, while 
maintaining specificity, and confer the ability to bind to a single site with high 
efficiency. These experiments are underway in the lab. 
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The final goal is to reach sufficient affinity enabling us to target endogenous genes 
either in promoter regions or in the transcribed regions in order to arrest transcription 
and demonstrate the anti-gene strategy in cells and in-vivo. 
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